Enhanced stability of inverse thermal gelling composite hydrogels

Patent metadata

Field	Value
Publication number	US-9205046-B2
Application number	US-77887910-A
Country	US
Kind code	B2
Filing date	May 12, 2010
Priority date	Apr 25, 2005
Publication date	Dec 8, 2015
Grant date	Dec 8, 2015

Abstract

The present invention relates to a composite hydrogel comprising a blend of an aqueous solution of an anionic polysaccharide or a derivative thereof, such as hyaluronan (also commonly referred to as hyaluronic acid) or a derivative thereof and an aqueous solution of methylcellulose or another water soluble cellulose derivative thereof, having dispersed polymeric particles, such as polymeric hydrophobic particles therein selected from micro particles and nanoparticles, and wherein the stability of the hydrogel is enhanced relative to the stability of the hydrogel alone. The polymeric particles may contain at least one therapeutic agent, in which case each therapeutic agent exhibits a linear sustained release rate that can be tuned or altered by selecting the appropriate polymer formulation of the micro particles and/or nanoparticles. The composite may be injectable, and in the absence of a therapeutic agent may be used as a bulking agent for reconstructive and cosmetic surgery or may act as a platform for subsequent delivery of therapeutic agents.

First claim

What we claim is:

1. A hydrogel composite comprising:
a hydrogel comprising a blend of a solution containing dissolved methylcellulose and a hyaluronan wherein the hyaluronan and the methylcellulose are present in a weight ratio of hyaluronan to methylcellulose in an amount of about 2:3; and dispersed hydrophobic polymeric particles selected from microparticles, being a particle size of 1 micron to 30 microns and nanoparticles being a particle size of from 10 nm to 1000 nm, wherein some or all of which hydrophobic polymeric microparticles and nanoparticles encapsulate at least one therapeutic agent and wherein the dispersed hydrophobic polymeric particles interact with the hydrogel through hydrophobic interactions between the hydrogel and the dispersed hydrophobic polymeric particles to alter the release of the at least one therapeutic agent, and wherein the stability of the hydrogel composite with the dispersed hydrophobic polymeric particles is enhanced relative to the stability of the hydrogel alone, and each of the at least one therapeutic agent has a sustained release profile that extends for about 28 days or more.

2. The hydrogel composite as claimed in claim 1 , wherein release of the at least one therapeutic agent is not dependent on gel formulation.

3. The hydrogel composite as claimed in claim 1 , wherein the hydrophobic polymer particles are selected from degradable and non-degradable hydrophobic polymers chosen from the group consisting of: aliphatic polyesters; polydioxanones; polyhydroxyalkanoate; polyanhydrides; aliphatic-aromatic polyesters; aliphatic polyamides; amide ester copolymers; urethane ester copolymers; urethane amide copolymers and urea ester copolymers; polyacrylates; ethylene-vinyl acetates; acyl substituted cellulose acetates; non-degradable polyurethanes; polystyrenes; polyvinyl chlorides; polyvinyl fluorides; poly(vinyl imidazoles); chlorosulphonate polyolefins; polyethylene oxides; starches; and blends or copolymers thereof; and
wherein the hydrogel comprises a blend of a solution containing dissolved methylcellulose and a solution containing dissolved hyaluronan.

4. The hydrogel composite as claimed in claim 1 , wherein the dispersed hydrophobic polymeric particles comprise a particle load of from about 1 to about 20 wt %, based on the composite.

5. The hydrogel composite as claimed in claim 1 , wherein the dispersed hydrophobic polymeric particles are selected from particle sizes of form about 50 nm to about 40 μm; and wherein the at least one therapeutic agent has a sustained, substantially liner release profile that extends for about 28 days or more.

6. The hydrogel composite as claimed in claim 1 , wherein the therapeutic agent is encapsulated in the dispersed hydrophobic polymeric particles in an amount in the range of from about 0.1 to about 30 wt % of particle mass;
wherein the hydrogel comprises a blend of a solution containing dissolved methylcellulose and a solution containing dissolved hyaluronan; and
wherein the at least one therapeutic agent has a sustained, substantially linear release profile that extends for about 28 days or more.

7. The hydrogel composite as claimed in claim 1 , wherein the aqueous solution is an aqueous solution selected from the group comprising water, saline, artificial cerebrospinal fluid, and buffered solutions;
wherein the hydrogel comprises a blend of a solution containing dissolved methylcellulose and a solution containing dissolved hyaluronan; and
wherein the at least one therapeutic agent has a sustained, substantially linear release profile that extends for about 28 days or more.

8. The hydrogel composite as claimed in claim 1 having an altered chemical functionality by the addition of at least one functional group to the hyaluronan or the methylcellulose selected from non-ionic polymers selected from the group consisting of carboxymethylcellulose sodium, hydrophobically modified hydroxyethyl cellulose, hydroxypropyl cellulose, and mixtures thereof, the functional group being selected from the group consisting of carboxylic acid, primary amine, aldehyde, hydrazide, maleimide, thiol, furan, alkyne, azide, alkene, urethane, and primary alcohol.

9. The hydrogel composite as claimed in claim 1 wherein the therapeutic agent is selected from the group comprising: anaesthetics for use in caudal, epidural, inhalation, injectable, retrobulbar, and spinal applications; analgesics, selected from the group comprising: acetaminophen, ibuprofen, fluriprofen, ketoprofen, voltaren, phenacetin and salicylamide; anti-inflammatories selected from the group comprising: naproxen and indomethacin; antihistamines, selected from the group comprising: chlorpheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, henyltoloxamine citrate, diphenhydramine hydrochloride, promethazine, brompheniramine maleate, dexbrompheniramine maleate, clemastine fumarate and triprolidine; antitussives selected from the group comprising: dextromethorphan hydrobromide and guaifenesin; expectorants; decongestants, selected from the group comprising: phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, and ephedrine; antibiotics selected from the group comprising: amebicides, broad and medium spectrum, fungal medications, monobactams and viral agents; bronchodilators selected from the group comprising: theophylline, albuterol and terbutaline; cardiovascular preparations selected from the group comprising: diltiazem, propranolol, nifedepine, clonidine, alpha adrenoceptor agonists, alpha receptor blocking agents, alpha and beta receptor blocking agents, antiotensin converting enzyme inhibitors, beta blocking agents, calcium channel blockers, and cardiac glycosides; central nervous system drugs selected from the group comprising: thioridazine, diazepam, meclizine, ergoloid mesylates, chlorpromazine, carbidopa and levodopa; metal salts selected from the group comprising: potassium chloride and lithium carbonate; minerals selected from the group consisting of iron, chromium, molybdenum and potassium; immunomodulators; immunosuppressives selected from the group comprising: minocycline, cyclosporine A; thyroid preparations selected from the group comprising: synthetic thyroid hormone, and thyroxine sodium; peptide and glycoprotein hormones and analogues selected from the group comprising: human chorionic gonadotrophin (HCG), corticotrophin, human growth hormone (HGH-Somatotrophin) and erythropoietin (EPO); steroids and hormones selected from the group comprising: ACTH, anabolics, androgen and estrogen combinations, androgens, corticoids and analgesics, estrogens, glucocorticoid, gonadotropin, gonadotropin releasing, hypocalcemic, menotropins, parathyroid, progesterone, progestogen, progestogen and estrogen combinations, somatostatin-like compounds, urofollitropin, vasopressin, methyl prednisolone, GM1 ganglioside, cAMP; and others; vitamins selected from the group comprising: water-soluble vitamins and veterinary formulations; growth factors selected from the group comprising: EGF, FGF2 and neurotrophin; peptides, peptide mimetics and other protein preparations; DNA; and, small interfering RNAs; with or without a pharmaceutically acceptable carrier or preservative; and
wherein the hydrogel composite has an altered rate of degradation by cross-linking the hyaluronan or by increasing the hydrophobicity of the hyaluronan.

10. A method for manufacturing a hydrogel composite as claimed in claim 1 which comprises the steps of 1) providing an aqueous solution of dissolved methylcellulose; 2) mixing hyaluronan into the aqueous solution, wherein the hyaluronan and the methylcellulose are present in a weight ratio of hyaluronan to methylcellulo

Assignees

• Shoichet Molly S
• Baumann M Douglas
• Kang Catherine Elizabeth
• Univ Toronto

Inventors

• Shoichet Molly S
• Baumann M Douglas
• Kang Catherine Elizabeth

Classifications

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K9/0095

  Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006) · CPC title

• A61K47/36

  Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title

• A61K38/1891

  Angiogenesic factors; Angiogenin · CPC title